Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts
Pfizer Inc. (NYSE: PFE) stock is trying to steady itself in late December after a volatile stretch driven by one big theme: the post-COVID hangover is still real, and 2026 is shaping up as another “rebuild” year—even as Pfizer spends aggressively to reload its pipeline.
As of Thursday, Dec. 18, 2025, Pfizer shares traded around $25.04, down about 1.8% from the prior close, according to the latest available trade time in the market feed.
What’s making Pfizer stock interesting right now isn’t a single headline—it’s the collision of several:
- Management’s 2026 outlook (revenue and earnings) that came in cautious versus expectations.
- A shifting U.S. drug-pricing landscape, where “most-favored-nation” style agreements are…
